👀 Copy Legendary Investors' Portfolios in One ClickCopy For Free

UPDATE 2-European stocks start the week strong on virus treatment hopes

Published 08/24/2020, 04:38 PM
Updated 08/25/2020, 12:10 AM
© Reuters.
AIRF
-
GRLS
-
AZN
-
BT
-
ICAG
-
STOXX
-
SX8P
-
SXEP
-
SX4P
-
SXPP
-

* Energy stocks lead gains
* Spain's Grifols jumps as U.S. authorises plasma treatment
* BT Group surges on report board to defend against takeover
bid
* Travel stocks among the few decliners

(Adds details, updates to close)
By Sruthi Shankar and Ambar Warrick
Aug 24 (Reuters) - European stocks marked their best day in
nearly two weeks on Monday as signs of progress in developing a
COVID-19 treatment offset fears about a resurgence in virus
cases stalling an economic recovery.
The pan-European STOXX 600 index .STOXX ended 1.6% higher,
after the U.S. health regulator said on Sunday it authorised the
use of blood plasma from patients who have recovered from
COVID-19 as a treatment. The day's gains came after a lacklustre week for regional
stocks, as a mix of low trading volumes, middling economic data
and an uptrend in COVID-19 cases weighed on sentiment.
"The weekend's vaccine news is at the fore," said Keith
Temperton, a sales trader at Forte Securities. "But we're in
this mid-summer volume vacuum, where the path of least
resistance is higher."
Spain's Grifols GRLS.MC , one of the world's top producers
of treatments based on human plasma, gained 1.6%.
AstraZeneca Plc AZN.L rose 2.1% after the Financial Times
reported the Trump administration was considering fast-tracking
an experimental COVID-19 vaccine being developed by the company,
while AstraZeneca marked further progress in the vaccine's
production. Oil and gas .SXEP was the best performing European sector,
adding some 3.4% as crude prices gained on weather-related
disruptions to supply. O/R
Automobile .SXAP , chemical .SX4P and bank .SX7P stocks
also rose more than 2%.
British telecoms company BT Group BT.L jumped around 7%
after a media report that its board was preparing to defend it
against takeover approaches from rivals and buyout firms.
UK government data showed on Friday the average number of
people that one COVID-19 infected person will pass the virus on
to had risen and may now be above 1, indicating a risk that the
overall epidemic is growing. Similarly, Germany, France and Spain have seen a surge in
virus cases, with their leaders looking at tightening travel
restrictions. "The way we're looking at the COVID narrative seems to be
changing. The market is looking at a better situation in terms
of hospitalisation and death rates," Temperton said.
Travel stocks .SXTP were among the few percentage
decliners for the day, as a rise in virus cases kept a recovery
in the sector on shaky ground. But Easyjet EZJ.L and Ryanair RYA.I rose more than 3.5%
each after brokerage UBS said it continued to prefer European
airlines which are more focused on domestic markets rather than
international ones, due to the pandemic.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.